Arunjyoti Bio Ventures Limited reported a net loss of ₹453.61 lakh for the financial year ended March 31, 2026, widening from a net loss of ₹27.62 lakh in the previous year. Revenue from operations for the period stood at ₹2,775.44 lakh, slightly lower than the ₹2,788.41 lakh recorded in FY25. The company’s total income for FY26 was ₹2,787.24 lakh.

The board has proposed changing the company name from Arunjyoti Bio Ventures Limited to Pasura Industries Limited to align with the group's corporate identity. This change requires shareholder approval via a special resolution at the upcoming Annual General Meeting (AGM) scheduled for August 12, 2026. The company has obtained name availability from the Registrar of Companies.

Financial Performance

The company’s financial performance was impacted by higher operating costs, employee expenses, and exceptional items. The profit before exceptional items and tax was a loss of ₹240.37 lakh. The board noted that the company incurred losses due to abnormal inventory consumption, increased manufacturing and operating costs, and under-utilization of manufacturing capacity.

Corporate Governance and Approvals

The board has sought shareholder ratification for several key proposals at the AGM. These include the ratification of a loan of up to ₹1 crore given to Pasura Xpress LLP, a related party. The company has already advanced ₹80.72 lakh to the LLP during FY26. The loan carries an interest rate of 10% per annum.

Additionally, the board has sought approval for the waiver of recovery of excess managerial remuneration paid to two Whole-time Directors. The excess remuneration amounted to ₹9,71,432 for Mr. Pabbathi Badari Narayana Murthy and ₹15,47,800 for Mr. Nadimpalli Vishal during FY26. The excess arose because the remuneration was paid on a net basis while the company bore the tax liability.

The board has also proposed increasing the remuneration of its Whole-time Directors. Mr. Pabbathi Badari Narayana Murthy’s remuneration is proposed to be increased to ₹8 lakh per month, while Mr. Nadimpalli Vishal and Mr. Dathvik Pabbathi are set to receive ₹5 lakh per month each, effective from April 1, 2026.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE485K01022/6a44e3fe-b35b-43bd-b940-481e523e4366.pdf

Arunjyoti Bio Ventures Limited returned to profitability in the first quarter of FY27, reporting a net profit of ₹61.24 lakh for the period ended June 30, 2026. This marks a significant recovery from the net loss of ₹204.54 lakh recorded in the corresponding quarter of the previous year. Revenue from operations for the quarter stood at ₹820 lakh, while total income reached ₹822.06 lakh.

The board approved the unaudited financial results and the Limited Review Report for the quarter ended June 30, 2026, at a meeting held on July 9, 2026. The results were reviewed by the Audit Committee and the Statutory Auditors. PKF Sridhar & Santhanam LLP, the Independent Auditor, conducted the limited review in accordance with the Standard on Review Engagement (SRE) 2410.

Financial Performance

The company's total expenses for the quarter were ₹740.22 lakh, a decrease from ₹655.54 lakh in the prior year period. Profit before exceptional items and tax was ₹81.84 lakh, compared to ₹216.91 lakh in Q1FY26. The tax expense for the quarter was ₹20.60 lakh, comprising a current tax of ₹12.44 lakh and a deferred tax charge of ₹8.16 lakh.

Key Financial Metrics

Corporate Governance Updates

In addition to the financial results, the board approved several key governance measures. The company will change its name from “Arunjyoti Bio Ventures Limited” to “Pasura Industries Limited,” subject to shareholder approval. This change necessitates alterations to the Articles of Association and Memorandum of Association.

The board accepted the resignation of M/s. Manoj Parakh & Associates as Secretarial Auditors effective July 9, 2026. Consequently, M/s. Vivek Surana & Associates were appointed as the new Secretarial Auditors to fill the casual vacancy. Their tenure extends until the conclusion of the next Annual General Meeting and for a period of five years, covering financial years 2026-27 to 2030-31, subject to member approval.

Furthermore, the board approved the waiver of recovery of excess managerial remuneration amounting to ₹25.19 lakh paid to Mr. Pabbathi Badhri Narayana Murthy, Whole-time Director, and Mr. Nadimpalli Vishal, Whole-time Director and CFO, for the financial year 2025-26. This waiver is also subject to shareholder approval.